Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay

References

• WintersS, MartinC, MurphyD, et al. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.29096890
   PubMed Web of Science ®Google Scholar
• VuongD, SimpsonPT, GreenB, et al. Molecular classification of breast cancer. Virchows Arch. 2014;465(1):1–14. doi:10.1007/s00428-014-1593-724878755
   PubMed Web of Science ®Google Scholar
• ParsonsHA, RhoadesJ, ReedSC, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res. 2020;26:2556–2564. doi:10.1158/1078-0432.CCR-19-300532170028
   PubMed Web of Science ®Google Scholar
• SchwarzenbachH, HoonD, PantelK. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–437. doi:10.1038/nrc306621562580
   PubMed Web of Science ®Google Scholar
• CrignaAT, SamecM, KoklesovaL, et al. Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope?EPMA J. 2020;11(4):1–25.32140182
   PubMed Web of Science ®Google Scholar
• IgnatiadisM, ReinholzM. Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res. 2011;13:222. doi:10.1186/bcr290622078011
   PubMed Web of Science ®Google Scholar
• NadalR, LorenteJA, RosellR, et al. Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies. Expert Rev Mol Diagn. 2013;13:295–307. doi:10.1586/erm.13.723570407
   PubMed Web of Science ®Google Scholar
• HallCS, KarhadeMG, Bowman BauldryJB, et al. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg. 2016;223:20–29. doi:10.1016/j.jamcollsurg.2016.02.02127049782
   PubMed Web of Science ®Google Scholar
• HassanEM, WillmoreWG, McKayBC, et al. In vitro selections of mammaglobin A and mammaglobin B aptamers for the recognition of circulating breast tumor cells. Sci Rep. 2017;7:14487. doi:10.1038/s41598-017-13751-z29101327
   PubMed Web of Science ®Google Scholar
• DanieleL, AnnaratoneL, AlliaE, et al. Technical limits of comparison of step-sectioning, immunohistochemistry and RT-PCR on breast cancer sentinel nodes: a study on methacarn-fixed tissue. J Cell Mol Med. 2009;13:4042–4050. doi:10.1111/j.1582-4934.2008.00449.x18671755
   PubMed Web of Science ®Google Scholar
• XenidisN, PerrakiM, KafousiM, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer Patients. J Clin Oncol. 2006;24:3756–3762. doi:10.1200/JCO.2005.04.594816769987
   PubMed Web of Science ®Google Scholar
• JägerD, StockertE, GureAO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001;61:2055–2061.11280766
   PubMed Web of Science ®Google Scholar
• JägerD, FilonenkoV, GouthI, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77–83. doi:10.1097/01.pai.0000213111.05108.a017536312
   PubMedGoogle Scholar
• NissanA, JägerD, RoystacherM, et al. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer. 2006;94:681–685. doi:10.1038/sj.bjc.660299216495929
   PubMed Web of Science ®Google Scholar
• Banys-PaluchowskiM, KrawczykN, FehmT. Potential role of circulating tumor cell detection and monitoring in breast cancer: a review of the current evidence. Front Oncol. 2016;6:255. doi:10.3389/fonc.2016.0025527990412
   PubMed Web of Science ®Google Scholar
• KrügerW, KrzizanowskiC, HolwegM, et al. Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol. 1996;122:679–686. doi:10.1007/BF012090328898979
   PubMed Web of Science ®Google Scholar
• StathopolouA, MavroudisD, PerrakiM, et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 2003;23:1883–1890.12820473
   PubMed Web of Science ®Google Scholar
• SchoenfeldA, KrugerKH, GommJ, et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase chain reaction for keratin 19. Eur J Cancer. 1997;33:854–861. doi:10.1016/S0959-8049(97)00014-29291805
   PubMed Web of Science ®Google Scholar
• KrügerWH, JungR, DetlefsenB, et al. Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med Oncol. 2001;18:33–38. doi:10.1385/MO:18:1:3311778968
   PubMed Web of Science ®Google Scholar
• XenidisM, IgnatiadisM, ApostolakiS, et al. Cytokeratin-19 mRNA positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009;27:2177–2184. doi:10.1200/JCO.2008.18.049719332733
   PubMed Web of Science ®Google Scholar
• ZachO, KasparuH, KriegerO, et al. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol. 1999;17:2015–2019. doi:10.1200/JCO.1999.17.7.201510561252
   PubMed Web of Science ®Google Scholar
• ChenY, ZouTN, WuZP, et al. Detection of cytokeratin 19, human mammaglobin and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers. 2010;25:59–68. doi:10.1177/17246008100250020120586026
   PubMed Web of Science ®Google Scholar
• MarquesAR, TeixeiraE, DiamondJ, et al. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat. 2009;114:223–232. doi:10.1007/s10549-008-0002-918409061
   PubMed Web of Science ®Google Scholar
• NtouliaM, StathopoulouA, IgnatiadisM, et al. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem. 2006;39:879–887. doi:10.1016/j.clinbiochem.2006.06.00916925986
   PubMed Web of Science ®Google Scholar
• Núñez-VillarMJ, Martínez-ArribasF, PollánM, et al. Elevated mammaglobin (hMAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res. 2003;5:R65–70. doi:10.1186/bcr58712793902
   PubMed Web of Science ®Google Scholar
• MikhitarianK, MartinRH, RuppelMB, et al. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer. 2008;8:55. doi:10.1186/1471-2407-8-5518289390
   PubMed Web of Science ®Google Scholar
• LiangDH, HallC, LucciA. Circulating tumor cells in breast cancer. Rec Results Cancer Res. 2020;215:127–145.
   PubMedGoogle Scholar
• ZhaoS, YangH, ZhangM, et al. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK 19 and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Cell Biochem Biophys. 2013;65:263–273. doi:10.1007/s12013-012-9426-222990361
   PubMed Web of Science ®Google Scholar
• ZhaoS, LiuYP, ZhangQY, et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res Treat. 2011;130:809–816. doi:10.1007/s10549-011-1379-421311967
   PubMed Web of Science ®Google Scholar
• IgnatiadisM, KallergiG, NtouliaM, et al. Prognostic value of the molecular detection of circulating tumour cells using a multimarker reverse transcription-PCR assay for Cytokeratin 19, Mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008;19:2593–2600. doi:10.1158/1078-0432.CCR-07-4758
   Web of Science ®Google Scholar
• MeloJV, YanXH, DiamondJ, et al. Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Leukemia. 1996;10:1217–1221.8684005
   PubMed Web of Science ®Google Scholar
• ReinholzMM, NibbeA, JonartLM, et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res. 2005;11:3722–3732. doi:10.1158/1078-0432.CCR-04-148315897569
   PubMed Web of Science ®Google Scholar
• HallC, ValadL, LucciA. Circulating tumor cells in breast cancer patients. Crit Rev Oncog. 2016;21:125–139. doi:10.1615/CritRevOncog.201601612027481009
   PubMedGoogle Scholar
• BenoyIH, ElstH, Van DamP, et al. Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clin Chem Lab Med. 2006;44:1082–1087. doi:10.1515/CCLM.2006.21016958599
   PubMed Web of Science ®Google Scholar
• LiGL, ZhangJ, JinKT, et al. Human mammaglobin: a superior marker for reverse transcriptase PCR in detecting tumor cells in breast cancer patients. Biomark Med. 2011;5:249–260. doi:10.2217/bmm.11.2021473729
   PubMed Web of Science ®Google Scholar
• KarczewskiKJ, SnyderMP. Integrative omics for health and disease. Nat Rev Genet. 2018;19:299–310. doi:10.1038/nrg.2018.429479082
   PubMed Web of Science ®Google Scholar
• FröhlichH, PatjoshiS, YeghiazaryanK, et al. Premenopausal breast cancer: potential clinical utility of a multi-omics based machine learning approach for patient stratification. EPMA J. 2018;11:175–186.
   Web of Science ®Google Scholar
• BozionellouV, MavroudisD, PerrakiM, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res. 2004;10:8185–8194. doi:10.1158/1078-0432.CCR-03-009415623593
   PubMed Web of Science ®Google Scholar